Cargando…

Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging

OBJECTIVE: Nitisinone induced hypertyrosinaemia is a concern in patients with Alkaptonuria (AKU). It has been suggested that this may alter neurotransmitter metabolism, specifically dopamine and serotonin. Herein mass spectrometry imaging (MSI) is used for the direct measurement of 2,4-diphenyl-pyra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davison, A. S., Strittmatter, N., Sutherland, H., Hughes, A. T., Hughes, J., Bou-Gharios, G., Milan, A. M., Goodwin, R. J. A., Ranganath, L. R., Gallagher, J. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488549/ https://www.ncbi.nlm.nih.gov/pubmed/31037385 http://dx.doi.org/10.1007/s11306-019-1531-4

Ejemplares similares

Correction to: Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging
por: Davison, Andrew S., et al.
Publicado: (2019)

Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria
por: Ranganath, L. R., et al.
Publicado: (2022)

Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria
por: Hughes, Juliette H., et al.
Publicado: (2020)

Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria
por: Ranganath, L.R., et al.
Publicado: (2022)

Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria
por: Norman, Brendan P., et al.
Publicado: (2022)

Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria
por: Milan, A. M., et al.
Publicado: (2019)

Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria
por: Davison, Andrew S., et al.
Publicado: (2022)

Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2020)

Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
por: Davison, Andrew S., et al.
Publicado: (2019)

Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial
por: Ooi, Nicola, et al.
Publicado: (2023)

Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone
por: Griffin, R., et al.
Publicado: (2018)

Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
por: Genovese, Federica, et al.
Publicado: (2023)

Fatal acute haemolysis and methaemoglobinaemia in a man with renal failure and Alkaptonuria – Is nitisinone the solution?
por: Davison, A.S., et al.
Publicado: (2020)

Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria—An approach using statistical modelling
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2021)

Long‐term low dose nitisinone therapy in adults with alkaptonuria shows no cognitive decline or increased severity of depression
por: Davison, Andrew S., et al.
Publicado: (2022)

Preventive use of nitisinone in alkaptonuria
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2021)

Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone
por: Imrich, Richard, et al.
Publicado: (2022)

Adequacy of nitisinone for the management of alkaptonuria
por: Abbas, Khawar, et al.
Publicado: (2022)

Increased prevalence of Parkinson's disease in alkaptonuria
por: Ranganath, Lakshminarayan, et al.
Publicado: (2023)

Vitiligo, alkaptonuria, and nitisinone—A report of three families and review of the literature
por: Ranganath, Lakshminarayan, et al.
Publicado: (2021)

Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism
por: Norman, Brendan P., et al.
Publicado: (2021)

First decade anniversary of the United Kingdom National Alkaptonuria Centre
por: Khedr, Milad, et al.
Publicado: (2023)

Clinical development of nitisinone for alkaptonuria (developakure) - a rare disease clinical trials design
por: Psarelli, Eftychia Eirini, et al.
Publicado: (2013)

Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients
por: Ahmad, Mohammad S. Z., et al.
Publicado: (2022)

Effects of Nitisinone on Oxidative and Inflammatory Markers in Alkaptonuria: Results from SONIA1 and SONIA2 Studies
por: Braconi, Daniela, et al.
Publicado: (2022)

Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria
por: Hughes, Juliette H, et al.
Publicado: (2019)

Development of an Effective Therapy for Alkaptonuria – Lessons for Osteoarthritis
por: Gallagher, James A., et al.
Publicado: (2021)

The nutritional status of people with alkaptonuria: An exploratory analysis suggests a protein/energy dilemma
por: Judd, Shirley, et al.
Publicado: (2020)

Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype
por: Neuckermans, Jessie, et al.
Publicado: (2023)

Clinical Features and Pharmacotherapy of Childhood Monoamine Neurotransmitter Disorders
por: Ng, J., et al.
Publicado: (2014)

Alkaptonuria: Current Perspectives
por: Zatkova, Andrea, et al.
Publicado: (2020)

Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2‐dioxygenase deficiency in the liver is responsible for homogentisic acid‐derived ochronotic pigmentation
por: Wilson, Peter J. M., et al.
Publicado: (2020)

Treatment of osteoporotic fractures in alkaptonuria by teriparatide stimulates bone formation and decreases fracture rate – A report of two cases
por: Ranganath, L.R., et al.
Publicado: (2021)

A case report of pregnancy in untreated alkaptonuria – Focus on urinary tissue remodelling markers
por: Ranganath, L.R., et al.
Publicado: (2021)

Detection of Changes in Monoamine Neurotransmitters by the Neonicotinoid Pesticide Imidacloprid Using Mass Spectrometry
por: Hirai, Anri, et al.
Publicado: (2022)

Analysis of the Phenotype Differences in Siblings with Alkaptonuria
por: Zatkova, Andrea, et al.
Publicado: (2022)

Pigmentation Chemistry and Radical‐Based Collagen Degradation in Alkaptonuria and Osteoarthritic Cartilage
por: Chow, Wing Ying, et al.
Publicado: (2020)

The Discovery of the Mode of Action of Nitisinone
por: Lock, Edward A.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mfsb2pbnemq92uldjujl341mb5